We are a multi-disciplinary systems biology lab where the research program is focused on the interface between chromatin regulation, cancer progression and drug resistance by utilizing novel computational, genomics and molecular techniques. Our research is focused on the following aspects:

1. Developing genomics and computational approaches for the identification of one-dimensional (1D) genomic regulatory elements and three-dimensional (3D) chromatin interactions from the various omics data through next generation sequencing (NGS) technologies such as ChIP-exo, ChIP-seq, MBDCap-seq, Epic-seq, DRIP-seq, TCC (Hi-C), RNA-seq and miRNA-seq;


2. Functionally and mechanistically characterizing the roles of epigenetic marks in cancer development and progression using novel techniques such as siRNA, 3C/ChIP/RT-qPCR, Western Blotting, 3D-FISH and CRISPR/Cas9;


3. Developing computational pipelines to aid molecular biomarker discovery and to examine the significance of identified gene signatures;


4. Adapting/applying genome-wide omics-seq techniques in patient tissues to identify epigenetic-driven therapeutic targets and markers.

We are working on various cancer models such as breast, prostate, pancreatic cancers, and leukemia.